Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag 2 Pitt research studies reveal enhanced melanoma treatment efficacy with combined PD1/LAG3 immunotherapies.

flag Two studies by University of Pittsburgh researchers in the Journal of Cell reveal insights into combination immunotherapies targeting immune checkpoints PD1 and LAG3. flag The studies show enhanced CD8+ T cell responses and improved cancer-killing abilities in melanoma patients treated with both drugs compared to monotherapies. flag The findings highlight the importance of understanding how these drugs can be combined to improve their effectiveness and suggest that LAG3-targeting drug, relatlimab, could be combined with other immunotherapies to enhance responses.

8 months ago
4 Articles

Further Reading